Literature DB >> 11445675

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

D C Angus1, W T Linde-Zwirble, J Lidicker, G Clermont, J Carcillo, M R Pinsky.   

Abstract

OBJECTIVE: To determine the incidence, cost, and outcome of severe sepsis in the United States.
DESIGN: Observational cohort study.
SETTING: All nonfederal hospitals (n = 847) in seven U.S. states. PATIENTS: All patients (n = 192,980) meeting criteria for severe sepsis based on the International Classification of Diseases, Ninth Revision, Clinical Modification.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We linked all 1995 state hospital discharge records (n = 6,621,559) from seven large states with population and hospital data from the U.S. Census, the Centers for Disease Control, the Health Care Financing Administration, and the American Hospital Association. We defined severe sepsis as documented infection and acute organ dysfunction using criteria based on the International Classification of Diseases, Ninth Revision, Clinical Modification. We validated these criteria against prospective clinical and physiologic criteria in a subset of five hospitals. We generated national age- and gender-adjusted estimates of incidence, cost, and outcome. We identified 192,980 cases, yielding national estimates of 751,000 cases (3.0 cases per 1,000 population and 2.26 cases per 100 hospital discharges), of whom 383,000 (51.1%) received intensive care and an additional 130,000 (17.3%) were ventilated in an intermediate care unit or cared for in a coronary care unit. Incidence increased >100-fold with age (0.2/1,000 in children to 26.2/1,000 in those >85 yrs old). Mortality was 28.6%, or 215,000 deaths nationally, and also increased with age, from 10% in children to 38.4% in those >85 yrs old. Women had lower age-specific incidence and mortality, but the difference in mortality was explained by differences in underlying disease and the site of infection. The average costs per case were $22,100, with annual total costs of $16.7 billion nationally. Costs were higher in infants, nonsurvivors, intensive care unit patients, surgical patients, and patients with more organ failure. The incidence was projected to increase by 1.5% per annum.
CONCLUSIONS: Severe sepsis is a common, expensive, and frequently fatal condition, with as many deaths annually as those from acute myocardial infarction. It is especially common in the elderly and is likely to increase substantially as the U.S. population ages.

Entities:  

Mesh:

Year:  2001        PMID: 11445675     DOI: 10.1097/00003246-200107000-00002

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  2000 in total

1.  Treatment of sepsis with activated protein C.

Authors:  C J Hinds
Journal:  BMJ       Date:  2001-10-20

2.  A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS.

Authors:  Laura E Fredenburgh; Mark A Perrella; Diana Barragan-Bradford; Dean R Hess; Elizabeth Peters; Karen E Welty-Wolf; Bryan D Kraft; R Scott Harris; Rie Maurer; Kiichi Nakahira; Clara Oromendia; John D Davies; Angelica Higuera; Kristen T Schiffer; Joshua A Englert; Paul B Dieffenbach; David A Berlin; Susan Lagambina; Mark Bouthot; Andrew I Sullivan; Paul F Nuccio; Mamary T Kone; Mona J Malik; Maria Angelica Pabon Porras; Eli Finkelsztein; Tilo Winkler; Shelley Hurwitz; Charles N Serhan; Claude A Piantadosi; Rebecca M Baron; B Taylor Thompson; Augustine Mk Choi
Journal:  JCI Insight       Date:  2018-12-06

3.  Melatonin augments apoptotic adipose-derived mesenchymal stem cell treatment against sepsis-induced acute lung injury.

Authors:  Hong-Hwa Chen; Chia-Lo Chang; Kun-Chen Lin; Pei-Hsun Sung; Han-Tan Chai; Yen-Yi Zhen; Yi-Ching Chen; Ying-Chung Wu; Steve Leu; Tzu-Hsien Tsai; Chih-Hung Chen; Hsueh-Wen Chang; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

4.  Exogenous carbon monoxide suppresses Escherichia coli vitality and improves survival in an Escherichia coli-induced murine sepsis model.

Authors:  Wei-chang Shen; Xu Wang; Wei-ting Qin; Xue-feng Qiu; Bing-wei Sun
Journal:  Acta Pharmacol Sin       Date:  2014-11-17       Impact factor: 6.150

5.  Association of triage hypothermia with in-hospital mortality among patients in the emergency department with suspected sepsis.

Authors:  Sriram Ramgopal; Christopher M Horvat; Mark D Adler
Journal:  J Crit Care       Date:  2020-07-16       Impact factor: 3.425

6.  Treatment with Fms-like tyrosine kinase 3 ligand reverses lung dendritic cell immunoparalysis and ameliorates zymosan-induced secondary lung injury in mice.

Authors:  H W Wang; W Yang; J Y Lu; G Tian; F Li; X H Wang; J R Kang; Y Yang
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

7.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

8.  Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells.

Authors:  Wei-Ching Huang; Yee-Shin Lin; Chi-Yun Wang; Cheng-Chieh Tsai; Hsiang-Chi Tseng; Chia-Ling Chen; Pei-Jung Lu; Po-See Chen; Li Qian; Jau-Shyong Hong; Chiou-Feng Lin
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

9.  Older Sepsis Survivors Suffer Persistent Disability Burden and Poor Long-Term Survival.

Authors:  Robert T Mankowski; Stephen D Anton; Gabriela L Ghita; Babette Brumback; Michael C Cox; Alicia M Mohr; Christiaan Leeuwenburgh; Lyle L Moldawer; Philip A Efron; Scott C Brakenridge; Frederick A Moore
Journal:  J Am Geriatr Soc       Date:  2020-04-15       Impact factor: 5.562

10.  Effects of aging on the immunopathologic response to sepsis.

Authors:  Isaiah R Turnbull; Andrew T Clark; Paul E Stromberg; David J Dixon; Cheryl A Woolsey; Christopher G Davis; Richard S Hotchkiss; Timothy G Buchman; Craig M Coopersmith
Journal:  Crit Care Med       Date:  2009-03       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.